...a VP at Amgen, where he ran process development. Montgomery also was a banker at Montgomery & Co....

...and managing directors George Montgomery and Keith Marshall. Montgomery and Marshall were managing directors at Montgomery & Co....

...this year, given the Obama administration's focus on healthcare reform. Banker tracks David Parrot joined Montgomery & Co....

...before year end. He noted that KaloBios took a step-up in valuation with this round. Montgomery & Co....

...Ventures; GBS Venture Partners; Sofinnova Ventures; Singapore BioInnovations; 5AM Ventures; and Lotus BioScience also participated. Montgomery & Co....

...IV Busulfex had $29.4 million in sales. The deal is expected to close next quarter. Montgomery & Co....

...was a VP and senior research analyst covering medical technology and life sciences companies at Montgomery & Co....

...display library from MorphoSys AG (FSE:MOR, Martinsried, Germany) (see BioCentury, April 2 & April 9). Montgomery & Co....

...VXGN and three from Raven. VXGN was advised by Lazard and Cooley Godward Kronish LLP. Montgomery & Co....

...75 million-dose contract for the company's rPA102 anthrax vaccine last December. Lazard advised VXGN, and Montgomery & Co....